Clinical Trials
23 trialsNCT06479954 2025-10-02
Non Interventional Study to Investigate the Safety and Effectiveness in Patients With Relapsed and Refractory Multiple Myeloma Treated With Elranatamab Under the Actual Use.
Pfizer
Active not recruiting
NCT06163040 2025-07-31
A Study to Evaluate the Safety of EmplicitiĀ® (Elotuzumab) When Treating Patients With Multiple Myeloma in Taiwan
Bristol-Myers Squibb
Completed
NCT07051850 2025-07-15
Quality of Life and Treatment Outcomes in RRMM Patients Receiving Advanced vs. Conventional Immunotherapies
Seoul St. Mary's Hospital
Recruiting
NCT02884102 2025-05-06
MMRF Molecular Profiling Protocol
Multiple Myeloma Research Foundation
Active not recruiting
NCT05673967 2025-04-25
Real-World Clinical Outcomes in Patients With Relapsed/Refractory Multiple Myeloma
Regeneron Pharmaceuticals
Completed
NCT03288974 2025-04-15
Pomalyst PMS
Celgene
Completed
NCT06825845 2025-02-13
Long Term Follow-up Observational Study in Patients Treated with Gene-Modified T-Cell Therapy
CARsgen Therapeutics Co., Ltd.
Not yet recruiting
NCT05986682 2025-02-03
Real-World Analysis of Belantamab Mafodotin Care Patterns in Patients With Relapsed and/or Refractory Multiple Myeloma
Duke University
Completed
NCT04721002 2023-10-18
MEDICI
AbbVie
Completed
NCT04409314 2023-08-21
Hypoxia-Specific Imaging to Predict Outcomes of Chimeric Antigen Receptor T-cell Therapy
University of California, San Francisco
Completed
NCT05217082 2023-06-09
A Study Assessing the Health-Related Quality of Life (HRQoL) in Participants With Relapsed and/or Refractory Multiple Myeloma (RRMM) With Triple Class Exposure
Bristol-Myers Squibb
Completed
NCT05887206 2023-06-02
Corneal Toxicity in Patients Treated by Belantamab Mafodotin
Centre Hospitalier Universitaire de Saint Etienne
Completed
NCT02164955 2022-10-20
A Post Authorisation Registry of IMNOVID (Pomalidomide) for Patients With Relapsed and Refractory Multiple Myeloma.
Celgene
Completed
NCT00900120 2021-09-21
Collecting and Storing Blood Samples From Patients With Cancer
Rutgers, The State University of New Jersey
Withdrawn
NCT03353545 2021-05-12
POWERFUL
Genesis Pharma S.A.
Completed
NCT03477643 2021-02-05
Retrospective Viability Study of the PETHEMA-POMCIDEX Clinical Practice Guidelines for the Treatment of Patients With Relapsed and Refractory Multiple Myeloma (RRMM)
PETHEMA Foundation
Completed
NCT02387879 2019-09-26
A Non-interventional,Observational Post Authorization Study of Patients With Multiple Myeloma Treated With Lenalidomide TR
Celgene
Unknown
NCT00949052 2018-08-16
Genetic Susceptibility and Risk of Second Cancers in Patients Who Have Undergone Stem Cell Transplant for Cancer
Vanderbilt-Ingram Cancer Center
Terminated
NCT00993694 2017-04-17
Methemoglobinemia in Young Patients With Hematologic Cancer or Aplastic Anemia Treated With Dapsone
Vanderbilt University Medical Center
Completed
NCT01430546 2016-03-25
Non-interventional Study on Time to Response and Quality of Life in Relapsed/Refractory Multiple Myeloma When Treated With Lenalidomide in Second Line
Karolinska University Hospital
Completed
NCT00008216 2014-06-06
Blood Stem Cell Transplant in Treating Patients With Hematologic Cancer
Columbia University
Terminated
NCT00898612 2014-03-10
Early Detection of Graft-Versus-Host Disease in Patients Undergoing a Donor Bone Marrow Transplant
Mayo Clinic
Withdrawn
NCT00957736 2013-05-14
Chronic Graft-Versus-Host Disease in Patients Who Have Undergone Donor Stem Cell Transplant
Vanderbilt-Ingram Cancer Center
Terminated